Loading insider details...
Beta
Latest Form 4 (Sep 17, 2026): Exercise/Conversion of 201 TARS shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | Tarsus Pharmaceuticals, Inc. (TARS) | Exercise/Conversion | 201 | n/a |
| Jun 29, 2026 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/Award | 3,837 | n/a |
| Jun 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Exercise/Conversion | 3,830 | n/a |
| May 22, 2026 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/Award | 671 | n/a |
| Apr 28, 2026 | Tarsus Pharmaceuticals, Inc. (TARS) | Exercise/Conversion | 1,383 | n/a |
| Feb 20, 2026 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/Award | 5,893 | n/a |
| Jun 10, 2025 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/Award | 30,000 | n/a |
| May 12, 2025 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/Award | 775 | n/a |
| Mar 25, 2025 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Exercise/Conversion | 7,440 | $661.8K |
| Jun 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Exercise/Conversion | 17,560 | $1.56M |